A comprehensive view of Weight Management Products. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Commentary: Weight-loss drugs could boost revenue of health-forward food chains, and benefit gut-health, fiber-rich, plant-based food companies; larger companies taking note, such as Unilever's plan to double number of products with healthy ingredients

Commentary: Food manufacturers downplaying negative impact of weight-loss drugs on business; Morningstar notes prior health trends like gluten-free, dairy-free and Adkins diet haven't derailed these companies in the past, citing interest waning over time

Goldman Sachs predicts 1% boost in US GDP if 60 million Americans take GLP-1 weight loss drugs by 2028, noting poor health impacts economic growth through missed days at work, early death, and informal caregiving that takes people out of the workforce

GLP-1 weight loss drugs, notably Semaglutide produced by Novo Nordisk, support Danish GDP growth; the drugs are also causing analysts to downgrade prospects for fast food companies

Morgan Stanley: Eli Lilly may become first biopharma firm to hit US$1T valuation with help of orally administered GLP-1 drug Orforglipron, whose phase 3 trial results are due in 2025; Lilly now offers injectable Tirzepatide under Mounjaro, Zepbound labels

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count